CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Hikma Pharmaceuticals PLC - HIK CFD

    20.71
    0.96%
    0.19
    Low: 20.56
    High: 20.94
    Market Trading Hours* (UTC) Opens on Wednesday at 07:00

    Mon - Fri: 07:00 - 11:00 11:03 - 15:30

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.19
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.025255 %
    Charges from full value of position ($-4.80)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.025255%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003337 %
    Charges from full value of position ($0.63)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003337%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency GBP
    Margin 5%
    Stock exchange United Kingdom of Great Britain and Northern Ireland
    Commission on trade 0%

    *Information provided by Capital.com

    Hikma Pharmaceuticals PLC ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 20.91
    Open* 20.73
    1-Year Change* 71.89%
    Day's Range* 20.56 - 20.94
    52 wk Range 11.75-22.22
    Average Volume (10 days) 329.07K
    Average Volume (3 months) 8.27M
    Market Cap 4.63B
    P/E Ratio 39.72
    Shares Outstanding 221.01M
    Revenue 2.19B
    EPS 0.53
    Dividend (Yield %) 2.28368
    Beta 0.43
    Next Earnings Date Feb 21, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 25, 2023 20.91 0.10 0.48% 20.81 21.16 20.72
    Sep 22, 2023 20.96 0.04 0.19% 20.92 21.08 20.74
    Sep 21, 2023 21.06 -0.08 -0.38% 21.14 21.37 20.95
    Sep 20, 2023 21.15 -0.02 -0.09% 21.17 21.49 20.99
    Sep 19, 2023 20.99 0.15 0.72% 20.84 21.10 20.83
    Sep 18, 2023 20.93 0.55 2.70% 20.38 20.96 20.38
    Sep 15, 2023 20.59 -0.35 -1.67% 20.94 21.03 20.42
    Sep 14, 2023 20.65 -0.13 -0.63% 20.78 20.89 20.60
    Sep 13, 2023 20.59 -0.17 -0.82% 20.76 20.85 20.58
    Sep 12, 2023 20.89 0.20 0.97% 20.69 21.05 20.38
    Sep 11, 2023 20.59 -0.21 -1.01% 20.80 21.03 20.39
    Sep 8, 2023 20.79 -0.07 -0.34% 20.86 21.00 20.54
    Sep 7, 2023 20.60 -0.25 -1.20% 20.85 20.86 20.60
    Sep 6, 2023 20.89 0.06 0.29% 20.83 21.06 20.61
    Sep 5, 2023 21.05 -0.37 -1.73% 21.42 21.49 21.05
    Sep 4, 2023 21.72 0.04 0.18% 21.68 21.89 21.55
    Sep 1, 2023 21.75 0.00 0.00% 21.75 21.92 21.56
    Aug 31, 2023 21.87 0.15 0.69% 21.72 22.11 21.64
    Aug 30, 2023 21.79 0.41 1.92% 21.38 21.89 21.38
    Aug 29, 2023 21.45 0.14 0.66% 21.31 21.53 21.20

    Hikma Pharmaceuticals PLC Events

    Time (UTC) Country Event
    Thursday, November 2, 2023

    Time (UTC)

    07:00

    Country

    GB

    Event

    November 2023 Hikma Pharmaceuticals PLC Trading Statement Release
    November 2023 Hikma Pharmaceuticals PLC Trading Statement Release

    Forecast

    -

    Previous

    -
    Wednesday, February 21, 2024

    Time (UTC)

    08:30

    Country

    GB

    Event

    Full Year 2023 Hikma Pharmaceuticals PLC Earnings Release
    Full Year 2023 Hikma Pharmaceuticals PLC Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 2517 2553 2341 2203 2076
    Revenue 2517 2553 2341 2203 2076
    Cost of Revenue, Total 1252 1252 1128 1108 1004
    Gross Profit 1265 1301 1213 1095 1072
    Total Operating Expense 2208 1955 1739 1669 1731
    Selling/General/Admin. Expenses, Total 509 488 464 453 437
    Research & Development 144 143 137 126 118
    Unusual Expense (Income) 200 -39 -76 -60 104
    Other Operating Expenses, Total 11 38 44 8 68
    Operating Income 309 598 602 534 345
    Interest Income (Expense), Net Non-Operating -65 -41 -33 -27 -39
    Other, Net -11 -13 -11 -16 -13
    Net Income Before Taxes 233 544 558 491 293
    Net Income After Taxes 191 420 430 487 285
    Minority Interest -3 1 1 -1 -3
    Net Income Before Extra. Items 188 421 431 486 282
    Net Income 188 421 431 486 282
    Income Available to Common Excl. Extra. Items 188 421 431 486 282
    Income Available to Common Incl. Extra. Items 188 421 431 486 282
    Dilution Adjustment 0
    Diluted Net Income 188 421 431 486 282
    Diluted Weighted Average Shares 225 233 238 243 242
    Diluted EPS Excluding Extraordinary Items 0.83556 1.80687 1.81092 2 1.16529
    Dividends per Share - Common Stock Primary Issue 0.55789 0.55055 0.50649 0.4714 0.37647
    Diluted Normalized EPS 2.03111 1.66094 1.4958 2.16049 1.90496
    Total Extraordinary Items 0
    Depreciation / Amortization 92 73 42 34
    Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Total revenue 1427 1304 1213 1337 1216
    Revenue 1427 1304 1213 1337 1216
    Cost of Revenue, Total 694 662 590 652 600
    Gross Profit 733 642 623 685 616
    Total Operating Expense 1184 1244 964 1082 873
    Selling/General/Admin. Expenses, Total 260 253 256 256 232
    Research & Development 64 75 69 84 59
    Depreciation / Amortization 43 49 43 44 29
    Unusual Expense (Income) 119 193 7 24 -63
    Other Operating Expenses, Total 4 12 -1 22 16
    Operating Income 243 60 249 255 343
    Interest Income (Expense), Net Non-Operating -41 -42 -34 -30 -24
    Net Income Before Taxes 202 18 215 225 319
    Net Income After Taxes 131 17 174 172 248
    Minority Interest 0 -2 -1 1 0
    Net Income Before Extra. Items 131 15 173 173 248
    Net Income 131 15 173 173 248
    Income Available to Common Excl. Extra. Items 131 15 173 173 248
    Income Available to Common Incl. Extra. Items 131 15 173 173 248
    Diluted Net Income 131 15 173 173 248
    Diluted Weighted Average Shares 222 222 228 234 232
    Diluted EPS Excluding Extraordinary Items 0.59009 0.06757 0.75877 0.73932 1.06897
    Dividends per Share - Common Stock Primary Issue 0.25 0.35715 0.19 0.37405 0.18
    Diluted Normalized EPS 1.14865 1.1982 0.83772 0.90171 0.75862
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 1999 2094 1922 1848 1668
    Cash and Short Term Investments 292 450 347 465 276
    Cash 159 155 85 94 112
    Cash & Equivalents 1 22 35 39 36
    Short Term Investments 132 273 227 332 128
    Total Receivables, Net 841 876 734 749 748
    Accounts Receivable - Trade, Net 777 781 662 637 654
    Total Inventory 776 695 757 568 528
    Prepaid Expenses 74 65 58 49 57
    Other Current Assets, Total 16 8 26 17 59
    Total Assets 4471 4372 4135 3930 3497
    Property/Plant/Equipment, Total - Net 1081 1146 1068 962 870
    Property/Plant/Equipment, Total - Gross 2008 1955 1841 1690 1549
    Accumulated Depreciation, Total -927 -809 -773 -728 -679
    Goodwill, Net 389 285 289 282 279
    Intangibles, Net 735 607 587 552 487
    Long Term Investments 52 46 34 29 38
    Other Long Term Assets, Total 215 194 235 257 155
    Total Current Liabilities 1077 1016 1028 1471 893
    Accounts Payable 291 262 279 286 263
    Accrued Expenses 171 194 175 173 185
    Notes Payable/Short Term Debt 75 64 117 60 65
    Current Port. of LT Debt/Capital Leases 73 57 51 518 10
    Other Current Liabilities, Total 467 439 406 434 370
    Total Liabilities 2336 1919 2000 1813 1812
    Total Long Term Debt 1135 725 764 107 562
    Long Term Debt 1074 651 692 48 539
    Capital Lease Obligations 61 74 72 59 23
    Deferred Income Tax 19 24 31 20 16
    Minority Interest 13 14 13 12 12
    Other Liabilities, Total 92 140 164 203 329
    Total Equity 2135 2453 2135 2117 1685
    Common Stock 40 42 41 41 40
    Additional Paid-In Capital 282 282 282 282 282
    Retained Earnings (Accumulated Deficit) 2129 2353 2011 2030 1618
    Treasury Stock - Common 0 -1 -1
    Other Equity, Total -316 -224 -199 -235 -254
    Total Liabilities & Shareholders’ Equity 4471 4372 4135 3930 3497
    Total Common Shares Outstanding 220.236 231.498 230.458 242.319 241.455
    Dec 2022 Jun 2022 Dec 2021 Jun 2021 Dec 2020
    Total Current Assets 1999 2144 2094 1955 1922
    Cash and Short Term Investments 292 393 450 346 347
    Cash & Equivalents 1 23 22 2 323
    Short Term Investments 132 94 273 101 24
    Total Receivables, Net 841 893 811 780 734
    Accounts Receivable - Trade, Net 777 784 719 693 662
    Total Inventory 776 765 695 736 757
    Prepaid Expenses 74 80 65 78 58
    Other Current Assets, Total 16 13 73 15 26
    Total Assets 4471 4747 4372 4180 4135
    Property/Plant/Equipment, Total - Net 1081 1132 1146 1061 1068
    Goodwill, Net 389 394 285 286 289
    Intangibles, Net 735 857 607 620 587
    Long Term Investments 52 52 46 36 34
    Other Long Term Assets, Total 215 168 194 222 235
    Total Current Liabilities 1077 1010 1016 960 1028
    Accounts Payable 291 255 262 226 279
    Accrued Expenses 171 160 194 145 175
    Notes Payable/Short Term Debt 75 76 64 132 117
    Current Port. of LT Debt/Capital Leases 73 61 57 49 51
    Other Current Liabilities, Total 467 458 439 408 406
    Total Liabilities 2336 2571 1919 1890 2000
    Total Long Term Debt 1135 1414 725 751 764
    Long Term Debt 1074 1340 651 676 692
    Capital Lease Obligations 61 74 74 75 72
    Deferred Income Tax 19 24 24 21 31
    Minority Interest 13 15 14 13 13
    Other Liabilities, Total 92 108 140 145 164
    Total Equity 2135 2176 2453 2290 2135
    Common Stock 40 41 42 41 41
    Additional Paid-In Capital 282 282 282 282 282
    Retained Earnings (Accumulated Deficit) 2129 2143 2353 2197 2011
    Treasury Stock - Common 0 0
    Other Equity, Total -316 -290 -224 -230 -199
    Total Liabilities & Shareholders’ Equity 4471 4747 4372 4180 4135
    Total Common Shares Outstanding 220.236 220.113 231.498 231.432 230.458
    Cash 159 276 155 243
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 233 544 558 491 293
    Cash From Operating Activities 530 638 464 472 430
    Cash From Operating Activities 372 145 91 73 69
    Amortization 26 40
    Non-Cash Items 112 108 84 34 116
    Cash Taxes Paid 55 129 61 108 63
    Cash Interest Paid 68 50 39 44 51
    Changes in Working Capital -187 -159 -269 -152 -88
    Cash From Investing Activities -607 -238 -283 -151 -96
    Capital Expenditures -225 -229 -224 -186 -139
    Other Investing Cash Flow Items, Total -382 -9 -59 35 43
    Cash From Financing Activities -58 -287 -298 -155 -278
    Financing Cash Flow Items -77 -53 -34 -48 -53
    Total Cash Dividends Paid -125 -120 -109 -97 -84
    Issuance (Retirement) of Stock, Net -303 0 -375
    Issuance (Retirement) of Debt, Net 447 -114 220 -10 -141
    Foreign Exchange Effects -21 -10 -2 0 -7
    Net Change in Cash -156 103 -119 166 49
    Dec 2022 Jun 2022 Dec 2021 Jun 2021 Dec 2020
    Net income/Starting Line 233 215 544 319 558
    Cash From Operating Activities 530 169 638 224 464
    Cash From Operating Activities 372 95 145 44 91
    Amortization
    Non-Cash Items 110 48 108 28 84
    Cash Taxes Paid 55 44 129 88 61
    Cash Interest Paid 68 27 50 25 39
    Changes in Working Capital -185 -189 -159 -167 -269
    Cash From Investing Activities -607 -506 -238 -104 -283
    Capital Expenditures -225 -119 -229 -94 -224
    Other Investing Cash Flow Items, Total -382 -387 -9 -10 -59
    Cash From Financing Activities -58 291 -287 -112 -298
    Financing Cash Flow Items -77 -33 -53 -26 -34
    Total Cash Dividends Paid -125 -83 -120 -78 -109
    Issuance (Retirement) of Debt, Net 447 710 -114 -8 220
    Foreign Exchange Effects -21 -9 -10 -9 -2
    Net Change in Cash -156 -55 103 -1 -119
    Issuance (Retirement) of Stock, Net -303 -303 0 0 -375
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Darhold Ltd Corporation 27.1507 60000000 0 2023-02-22 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 5.2296 11556882 0 2023-02-22 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 4.5268 10003617 -1477940 2023-06-12 LOW
    Columbia Threadneedle Investments (UK) Investment Advisor/Hedge Fund 2.0123 4446848 -117201 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.9841 4384669 -6243 2023-06-01 LOW
    Mawer Investment Management Ltd. Investment Advisor 1.7745 3921529 -1080 2023-04-30 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.7473 3861317 0 2023-08-01 LOW
    Schroder Investment Management Ltd. (SIM) Investment Advisor/Hedge Fund 1.6069 3550974 -11213 2023-08-01 LOW
    Fidelity International Investment Advisor 1.4889 3290345 0 2023-08-01 LOW
    Polar Capital LLP Investment Advisor/Hedge Fund 1.3193 2915402 997499 2023-06-30 LOW
    Epoch Investment Partners, Inc. Investment Advisor 0.9957 2200383 9231 2023-06-01 LOW
    Aegon Asset Management Ltd Investment Advisor 0.9857 2178181 -101093 2023-08-01 LOW
    Baillie Gifford & Co. Investment Advisor 0.9057 2001573 62506 2022-12-12 LOW
    M & G Investment Management Ltd. Investment Advisor 0.6445 1424294 -28906 2023-08-01 LOW
    Premier Asset Management Ltd Investment Advisor/Hedge Fund 0.6352 1403728 9290 2023-05-31 LOW
    Darwazeh (Mazen Samih Taleb) Individual Investor 0.6116 1351507 43150 2023-04-17 LOW
    BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.5944 1313546 84436 2023-08-01 LOW
    Al-Husry (Ali) Individual Investor 0.5262 1162811 0 2023-02-22 LOW
    Newton Investment Management Ltd. Investment Advisor 0.5211 1151544 -30125 2023-06-30 LOW
    GAM International Management Ltd. Investment Advisor/Hedge Fund 0.5023 1110079 217500 2022-12-12 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Hikma Company profile

    Discover the latest Hikma share price today with our comprehensive live chart.

    Hikma Pharmaceuticals plc. (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. The company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics.

    Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The Hikma’s branded division offers 499 products in 1,256 dosage strength. The most popular products are: Amoclan, Omnisef, Blopress and Suprax. The injectables division vendors 200 products in 379 dosage forms.

    Hikma pharmaceuticals share price is set and traded on the London Stock Exchange (LSE) under the ticker symbol HIK. The company constitutes the FTSE 100 and FTSE 350 Indices.

    Hikma made an initial public offering on 11 November 2005, and Hikma pharmaceuticals shares were listed for the first time, raising gross proceeds of $124 million.

    Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, it became the first Arab company to export pharmaceutical products to the US.

    The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquisitions helped Hikma to establish itself as the world’s leading provider in its industry.

    In May 2014, Hikma Pharmaceuticals plc significantly increased its presence in the injected medicine market by purchasing assets from the US generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million.

    The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma's position in a non-injectables business in the US market.

    Hikma has been recognised as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a row: from 2014 to 2017. 

    According to Hikma’s latest earnings report, the company delivered strong growth in revenue and profit in 2019 with a group core revenue of $2,203 million (up 6 per cent) and operating profit of $508 million (up 10 per cent).

    Follow the Hikma share price today with Capital.com to spot the best trading opportunities. Track all the ups and downs of the HIK stock price and stay on top of the latest price fluctuations with our live Hikma stock chart.

    Industry: Pharmaceuticals (NEC)

    1 New Burlington Place
    LONDON
    W1S 2HR
    GB

    Income Statement

    • Annual
    • Quarterly

    News

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023

    People also watch

    BTC/USD

    26,206.30 Price
    -0.560% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    Oil - Crude

    90.12 Price
    +0.660% 1D Chg, %
    Long position overnight fee 0.0445%
    Short position overnight fee -0.0664%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    US100

    14,567.60 Price
    -1.490% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    XRP/USD

    0.51 Price
    -0.120% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading